Cargando…

Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma

Anti-PD-1 immunotherapy has been extensively used in treatment of patients with advanced metastatic renal cell carcinoma (mRCC). Several prospective clinical trials showed that the combined treatment of anti-PD-1 antibody plus lenvatinib, a potent receptor tyrosine kinase inhibitor (TKI), exhibited...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Tingting, Lin, Xiaotong, Ling, Jing, Wang, Rong, Chen, Yue, Cai, Longmei, Sun, Jingyuan, Wu, Dehua, Xie, Guozhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895929/ https://www.ncbi.nlm.nih.gov/pubmed/36742302 http://dx.doi.org/10.3389/fimmu.2023.1115691

Ejemplares similares

PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma
por: Parakh, Sagun, et al.
Publicado: (2021)

Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study
por: Cai, Mingyue, et al.
Publicado: (2022)

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
por: Zhu, Chengpei, et al.
Publicado: (2023)

Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
por: Jiang, Youhai, et al.
Publicado: (2020)

Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies
por: Chen, Meng, et al.
Publicado: (2022)

PD-1 Blockade on Tumor Microenvironment-Resident ILC2s Promotes TNF-α Production and Restricts Progression of Metastatic Melanoma
por: Howard, Emily, et al.
Publicado: (2021)

Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinoma
por: Yang, Jieying, et al.
Publicado: (2023)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
por: Zhang, Yuedi, et al.
Publicado: (2022)

Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy
por: Razaghi, Ali, et al.
Publicado: (2023)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications
por: Sun, Xuqi, et al.
Publicado: (2022)

PD-1 Blockade Reverses Obesity-Mediated T Cell Priming Impairment
por: Le, Catherine T., et al.
Publicado: (2020)

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
por: Stoff, Ronen, et al.
Publicado: (2023)

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
por: Xu-Monette, Zijun Y., et al.
Publicado: (2017)

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion
por: Alvarez, Maite, et al.
Publicado: (2020)

The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer
por: Zhao, Zihan, et al.
Publicado: (2023)

Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts
por: Yuan, Guosheng, et al.
Publicado: (2022)

Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti–PD–1 antibody
por: Xu, Bin, et al.
Publicado: (2022)

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
por: Bendtsen, Mathias Alrø Fichtner, et al.
Publicado: (2017)

PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
por: Wu, Yilun, et al.
Publicado: (2019)

Bv8 Blockade Sensitizes Anti-PD1 Therapy Resistant Tumors
por: Benguigui, Madeleine, et al.
Publicado: (2022)

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
por: Zuazo, Miren, et al.
Publicado: (2020)

Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Mei, Jie, et al.
Publicado: (2021)

A novel [(89)Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer
por: Puyalto, Ander, et al.
Publicado: (2023)

Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study
por: Jia, Meng, et al.
Publicado: (2022)

Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade
por: Aoki, Tomoko, et al.
Publicado: (2020)

Immune Protection of SIV Challenge by PD-1 Blockade During Vaccination in Rhesus Monkeys
por: Pan, Enxiang, et al.
Publicado: (2018)

Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
por: Li, Shuqun, et al.
Publicado: (2023)

The role of (18)F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy
por: Wang, Guanyun, et al.
Publicado: (2023)

Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis
por: Liu, Kewei, et al.
Publicado: (2022)

Irreversible electroporation combined with chemotherapy and PD-1/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer
por: Ma, Yangyang, et al.
Publicado: (2023)

Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma
por: Yan, Kai, et al.
Publicado: (2023)

Unexpected Favorable Outcome to PD-1 Antibody Plus Lenvatinib in a Patient With Recurrent Intestinal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Review
por: Lei, Yanna, et al.
Publicado: (2021)

Corrigendum: The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy
por: Wang, Guanyun, et al.
Publicado: (2023)

PD-1 Blockade Modulates Functional Activities of Exhausted-Like T Cell in Patients With Cutaneous Leishmaniasis
por: Garcia de Moura, Renan, et al.
Publicado: (2021)

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells
por: Viramontes, Karla M., et al.
Publicado: (2022)

Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
por: Mabbitt, Joseph, et al.
Publicado: (2023)

A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine
por: Abdoli Shadbad, Mahdi, et al.
Publicado: (2022)

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma
por: Hu, Zhang-Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3g8u4lpjfunk6hh86gj4q43hk6